GLP (Good Laboratory Practice) toxicology studies typically progress from rodents (usually rats) to non-rodent species (often dogs) for several important reasons:1. Species differences: Rats and dogs may metabolize drugs differently or show varied responses to compounds. Testing in both species provides a more comprehensive safety profile[2].2. Regulatory requirements: Many regulatory agencies require testing in both rodent and non-rodent species before human trials can begin. This helps identify potential toxicities that may be species-specific[2].3. Physiological similarities: Dogs share more physiological similarities with humans in certain aspects, making them a valuable model for predicting human responses[2].4. Dose extrapolation: Using two species allows for better dose extrapolation and safety margin calculations for human trials.5. Longer-term studies: Dogs have longer lifespans than rats, enabling extended toxicity studies that better mimic human drug use durations.6. Cardiovascular assessment: Dogs are particularly useful for evaluating cardiovascular effects of drugs, which is crucial for safety assessment[2].By testing in both rats and dogs, researchers can gather more comprehensive safety data, better predict potential human toxicities, and meet regulatory requirements for drug development.Sources[1] Central Nervous System GLP-1 Receptors Regulate Islet Hormone ... https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5505222/[2] Preclinical GLP Neurotoxicology - MD Biosciences https://www.mdbneuro.com/glp-nonclinical-safety-neurotoxicology[3] 4-Week repeated dose rat GLP toxicity study of oncolytic ECHO-7 ... https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7840795/[4] Simultaneous assessment of central nervous and respiratory ... https://www.sciencedirect.com/science/article/pii/S1056871923000199[5] Behavioral tests in rodent models of stroke - PMC - NCBI https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8315143/
- Forums
- ASX - By Stock
- Ann: Brain Injury Program GLP Studies Further Update
NYR
nyrada inc.
Add to My Watchlist
17.5%
!
23.5¢

GLP (Good Laboratory Practice) toxicology studies typically...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
23.5¢ |
Change
0.035(17.5%) |
Mkt cap ! $49.56M |
Open | High | Low | Value | Volume |
20.0¢ | 23.5¢ | 20.0¢ | $405.2K | 1.907M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 31257 | 23.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
24.0¢ | 103993 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 31257 | 0.235 |
1 | 2644 | 0.225 |
2 | 157237 | 0.215 |
1 | 70000 | 0.210 |
2 | 100000 | 0.205 |
Price($) | Vol. | No. |
---|---|---|
0.240 | 103993 | 4 |
0.245 | 3000 | 1 |
0.250 | 148059 | 3 |
0.260 | 21276 | 1 |
0.275 | 50000 | 1 |
Last trade - 16.10pm 17/06/2025 (20 minute delay) ? |
Featured News
NYR (ASX) Chart |
The Watchlist
RC1
REDCASTLE RESOURCES LIMITED
Ronald Miller, Non-Executive Director
Ronald Miller
Non-Executive Director
SPONSORED BY The Market Online